BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

SA Transcripts 161.77K Followers Follow BioMarin Pharmaceutical Inc. ( BMRN ) Canaccord Genuity's 46th Annual Growth Conference August 12, 2026 8:00 AM EDT Company Participants Brian Mueller - CFO & Executive VP of Finance Conference Call Participants Whitney Ijem - Canaccord Genuity Corp., Research Division Presentation Whitney Ijem Canaccord Genuity Corp., Research Division All right. Good morning, everyone. Thank you so much for joining us. My name is Whitney Ijem. I'm one of the biotech analysts here at Canaccord. And it's my pleasure to introduce BioMarin Pharmaceutical this morning. And on behalf of BioMarin, we have Brian Mueller, CFO. Thank you for being here. Question-and-Answer Session Whitney Ijem Canaccord Genuity Corp., Research Division So just to start off high level for anybody who's not familiar, for anybody who that might be, I don't know, BioMarin is a household name. But for anybody who is not familiar, can you briefly introduce the story, like who is BioMarin currently? And where are you trying to go over the next 5, 10 years? Brian Mueller CFO & Executive VP of Finance Yes. Thanks, Whitney, for having us. Really glad to be here. Thanks, everyone, joining in person and those online. Yes. So I do think there are some folks that may not be familiar with BioMarin. So I thought I'd give a little bit of maybe the past, present and future, and then we can get into more details in the business. So BioMarin Pharmaceutical is one of the largest rare disease-focused companies. The company has been operating for a bit over 25 years. And it's interesting back when we started our journey, there were only a handful of rare disease companies. There was BioMarin, there was Genzyme, Shire, TKT. However, those other companies are now part of larger pharmaceutical companies because they were acquired over the years. And while now there's hundreds of other rare disease companies, BioMarin spent